NHCFOODS: Consolidating at Macro Support Aft Volatile CorrectionOverview :
NHC Foods Limited (BSE: 517554) is currently navigating a period of consolidation on the daily (1D) timeframe. After peaking at a 52-week high of ₹1.35, the stock has experienced significant volatility and corrective pressure, now trading near the ₹1.06 level. The company, a nano-cap entity in the FMCG sector, has recently seen a notable expansion in its equity base following FCCB conversions, which continues to influence market sentiment.
Trend Direction (Moving Averages) :
MA Ribbon/EMA Analysis : The stock is currently trading in a tight range relative to its short-term moving averages. With the 5-day, 10-day, 20-day, and 50-day SMAs all clustered near the ₹1.10 level, the price is currently suppressed by this overhead resistance. However, it maintains a position slightly above its 200-day SMA (approx. ₹1.00), suggesting that the long-term bullish trend remains precariously intact.
Momentum Indicators :
RSI (Relative Strength Index) : The RSI(14) is currently in the 42–44 range. This indicates a neutral to slightly bearish momentum. It is neither overbought nor oversold, suggesting a lack of decisive trend-driving volume.
MACD : The MACD line remains below its signal line and the zero line, which is traditionally viewed as a bearish signal, reflecting the lack of upward momentum seen over the past month.
Fibonacci : The stock is testing levels that align with recent structural support. A breakdown below the ₹1.00 psychological floor would likely signal a retest of the 52-week low near ₹0.59.
Key Levels to Watch :
Resistance : The immediate hurdle is the ₹1.10–₹1.11 zone (the cluster of short-term moving averages and the recent high). A volume-backed breakout above ₹1.15 is required to shift the bias to bullish.
Support : The primary support zone sits at ₹1.00–₹1.05. If the price fails to hold the ₹1.00 level, the stock may enter a deeper retracement phase.
Directional Bias: NEUTRAL / CAUTIOUS
The stock is in a "wait-and-see" phase. Until NHCFOODS can decisively clear the ₹1.11 resistance with significant trading volume, the risk of sideways consolidation or a drift toward support remains higher than the probability of an impulsive breakout.
Disclaimer : This analysis is for educational purposes only and does not constitute financial advice. Nano-cap stocks like NHC Foods carry high volatility and liquidity risks; please manage your position sizing accordingly. 
Long
Long
RECLTD: A Possible Elliott Wave Roadmap for Wave ⑤With Wave ④ appearing complete, RECLTD may be at the beginning of Wave ⑤ of the larger Wave III.
The chart presents one possible Elliott Wave roadmap for how Wave ⑤ could unfold.
=> Proposed Structure
(1): Initial impulsive advance with a projected move of approximately 84.23%.
(2): Corrective pullback.
(3): If the Elliott Wave structure develops as expected, this wave could become the strongest and longest segment.
(4): Consolidation.
(5): Final push to complete Wave ⑤, which would also complete the larger Wave III, with a projected advance of approximately 942.25%.
📊 Technical Structure
✅ Long-term ascending channel remains intact.
✅ The projected roadmap anticipates the development of Wave (1), (2), (3), (4), and (5) to complete ⑤, which in turn completes Wave III.
These projections are illustrative, not guaranteed price targets, and are meant to visualize one potential path if the bullish Elliott Wave count continues to unfold.
❌ Invalidation
The current Elliott Wave count remains valid as long as price holds above ₹303.00.
A decisive break below this level would invalidate this bullish scenario.
*******************************************************************************************
Warning ⚠
This analysis is shared for educational purposes and reflects one possible Elliott Wave interpretation. It is not financial advice.
*******************************************************************************************
#RECLTD #ElliottWave #Wave3 #ImpulseWave #TechnicalAnalysis #WaveAnalysis #TradingView #PriceAction #StockMarket #SwingTrading #PositionalTrading #MarketStructure #NSE #NikhilKanal #ElliottWave #LeadingDiagonal #Zigzag #DoubleZigzag #TripleZigzag #CorrectiveWaves #WaveAnalysis #TechnicalAnalysis #TradingEducation #PriceAction #TradingView #MarketStructure #StockMarket #NikhilKanal #ElliottWave #TradingEducation #MotiveWave #ImpulseWave #LeadingDiagonal #EndingDiagonal #WaveAnalysis #TechnicalAnalysis #PriceAction #TradingView #StockMarket #MarketStructure #TradingPsychology #NikhilKanal #ElliottWave #TradingEducation #LeadingDiagonal #EndingDiagonal #Triangle #WaveAnalysis #TechnicalAnalysis #PriceAction #TradingView #MarketStructure #NikhilKanal #ElliottWave 
Long
Short
Short
Long
Long
Long
Long
Long
Long
Long
Long
GAUDIUM IVF – TECHNICAL + FUNDAMENTAL BREAKOUT
*** Strong Bullish Momentum Confirmed (Chart + Data Match)
Stock recently made a fresh breakout near the ₹140 zone
Trading near 52-week high (₹133–₹137 zone earlier)
Clear Higher High – Higher Low structure → Strong uptrend continuation
🟢 Demand Zone: ₹128 – ₹132
🟡 Retracement Zone: Perfect bounce area
🔴 Premium Zone: Above ₹140 (current price area)
Institutions likely active near the demand zone
About the Company
Gaudium IVF and Women Health Limited is one of India's leading IVF (In-Vitro Fertilization) chains, founded in March 2015 by Dr. Manika Khanna and Dr. Peeyush Khanna in Delhi. It is a healthcare services company focused on fertility treatment, women's health, and assisted reproductive technology (ART).
The company operates through a Hub-and-Spoke model — 7 Hubs (full-service IVF centers) and 28 Spokes (strategic alliances with infertility experts) across 9 states in India, totaling 30+ locations.
It was successfully listed on NSE & BSE on February 27, 2026, at an issue price of ₹79/share.
CEO & Founder — Dr. Manika Khanna
Detail Information
Designation Chairperson & Managing Director (CMD)
Education MBBS (Gold Medallist), MD in Obstetrics & Gynecology — Maharaja Sayajirao University of Baroda
Specialization Advanced Gynecological Endoscopic Surgery — Kiel, Germany
Experience 16+ years in IVF treatment
Awards Delhi Ratna Award (2008), Women Excellence Award (2016), Oxford Academy UK — Medical Science Global Women's Health (2021), BusinessWorld Healthcare Personality of the Year — Women (2017)
Dr. Manika Khanna is the primary driving force behind Gaudium IVF. She is not just the clinical head but also the strategic and business leader of the company. She was also the selling shareholder in the IPO's Offer for Sale, divesting ~94.93 lakh shares worth ₹75 crore
Business Model
Gaudium IVF operates a diversified, patient-centric revenue model:
Revenue Stream Contribution
IVF Treatment 64%
Pharmacy 31%
Hospital Services 4%
The pharmacy segment grew from just 0.50% in FY23 to 28.85% in FY25 — a massive margin-enhancing shift.
Patient Journey: Lead generation → Consultation → Stimulation → OPU (Ovum Pick-Up) → Embryo Transfer → Post-care. Approximately 70% of the package amount is collected by the OPU stage, ensuring strong cash flow visibility.
Key Differentiators:
• GAAT (Gaudium Advanced Analysis and Treatment) — proprietary genome-based personalization system
• 58.74% IVF success rate (as of Sept 2025) vs. industry average
• Focus on complex/high-risk IVF cases (patients with 10–15 failed cycles)
• ₹7.39 crore invested in R&D as of March 2025
• Average Revenue per Patient: ₹3.55 lakh
• IVF in India costs ₹3–4 lakh vs. ₹18 lakh in the US — strong medical tourism advantage
Shareholding Pattern (Latest: FY27 Q1)
Category Holding %
Promoters 71.29%
FII (Foreign Institutional) 3.02%
DII (Domestic Institutional) 2.22%
Public 16.78%
Others 6.69%
>> Promoter holding is strong at 71.29% — zero pledging reported
Growth Strategy & Expansion Plans Year Expansion Plan FY27 - 3 new hubs launching (2 in Delhi/NCR, 1 in Nagpur) FY28 8 new centres planned FY29 1 additional centre
360° Customer Acquisition Strategy:
1. Digital Marketing (50%) — performance marketing, Tier II/III city targeting
2. Word of Mouth (30%) — strong patient & doctor networks
3. PR (10%) — media, celebrity partnerships
4. Brand Building (10%) — ATL/BTL advertising
Key Growth Drivers:
1. 13% national infertility rate — 27.5 million couples affected
2. India's Total Fertility Rate fell to 1.9 (below the replacement level of 2.1)
3. Technological advances — AI embryo selection, time-lapse incubators, genetic testing (PGT)
4. Expansion into Tier 2 & Tier 3 cities
5. Medical tourism — India's IVF costs are 80% cheaper than the US
6. ART (Regulation) Act providing regulatory clarity
Debt/Equity 0.52 (manageable)
Sector Tailwind Strong — 13%+ CAGR IVF market
Expansion Aggressive — 12 new centres by FY29
“Strong breakout stock with solid fundamentals like 25% ROE & expansion plans. Brokers positive but valuation expensive. Best strategy: Buy on dips, not at highs. Momentum intact with upside potential.”
Long
Long
Long
Long
